Eli Lilly's Lormalzi: A Breakthrough Alzheimer's Treatment Comes to India

Eli Lilly and Company is introducing Lormalzi, a novel Alzheimer's treatment, in India. This injectable therapy targets amyloid plaques, the main culprit of cognitive decline in Alzheimer's patients. Expected to assist those with mild symptoms, Lormalzi marks a significant stride in disease-modifying therapies.

Eli Lilly and Company is set to launch its groundbreaking Lormalzi injection in India this month, designed to treat Alzheimer's disease at its early stages. The announcement was made by Winselow Tucker, President and General Manager of Eli Lilly (India).

Lormalzi, utilizing donanemab, targets amyloid plaques—a primary factor contributing to cognitive decline in Alzheimer's patients. Priced at ₹91,688 per month, the treatment offers a new hope, specifically for patients with mild cognitive impairment or those in the early dementia stage.

The availability of Lormalzi aligns with the forecasted increase in India's dementia cases, potentially doubling by 2036. Eli Lilly aims to broaden access through an alternative program, reinforcing its commitment to innovative treatments for Alzheimer's patients.